Stockwinners Market Radar for August 09, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:12 EDT Online Education Services selects Juniper solutions for networking needs - Juniper Networks "announced that Online Education Services, an online education enabler, has selected Juniper's wired and wireless solutions to power its networking experience."

20:10 EDT Cathie Wood's ARK Investment bought 129.8K shares of Teladoc today

19:00 EDT MediciNova says MN-001 abstract accepted for presentation at IDF 2022 Congress - MediciNova announced an abstract entitled "Improvement of Serum Lipid Panel by Tipelukast (MN-001) in Type 2 Diabetes and NAFLD Patients" has been accepted and selected for poster presentation at the International Diabetes Federation 2022 Congress to be held December 5 - 8, 2022. MediciNova's Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, will present the results of the study. Presentation details will be disseminated as they become available. Kazuko Matsuda, M.D. Ph.D., M.P.H., Chief Medical Officer, MediciNova, Inc., commented, "We are very pleased to present the additional findings from our completed Phase 2 trial in which MN-001 improved serum lipid profile in the NAFLD participants with Type 2 diabetes more significantly than in the NAFLD participants without Type 2 diabetes. This subgroup analysis was conducted based on in-vitro research findings that MN-001 down regulated CD36 mRNA and upregulated ABCG1 mRNA."

18:31 EDT Catalent to acquire Metrics Contract Services for $475M - Catalent "announced that it has reached an agreement to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, North Carolina, for $475M from Mayne Pharma Group Limited. Upon completion, the acquisition will strengthen Catalent's capabilities in integrated oral solid formulation development, manufacturing, and packaging to help customers simplify and accelerate their programs, while also expanding Catalent's capacity to handle highly potent compounds. The acquisition is expected to close before the end of this calendar year, subject to customary closing conditions, and the entire team of over 400 employees will join Catalent."

17:58 EDT Aziyo Biologics names co-founder C. Randal Mills as CEO - Aziyo Biologics "announced that Aziyo co-founder C. Randal Mills, Ph.D. has assumed the President and CEO role on an on-going basis. Dr. Mills, who is internationally recognized for his contributions to the field of regenerative medicine, has served as the Company's interim CEO since June 2022."

17:50 EDT Lockheed Martin awarded $540.1M Navy contract modification - Lockheed Martin was awarded a not-to-exceed $524.1M undefinitized modification to a previously awarded fixed-price incentive advanced acquisition contract. This modification increases the ceiling to procure long-lead time materials, parts, components, and effort for the production of seven Lot 15 F-35A aircraft, two Lot 15 F-35B aircraft, seven Lot 16 F-35A, and two Lot 16 F-35B aircraft for the government of Italy. Work is expected to be completed in June 2025. Non-U.S. Department of Defense participant funds in the amount of $524.1Mwill be obligated at the time of award, none of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

17:45 EDT MasterCraft Boat announces review of strategic alternatives for NauticStar - MasterCraft Boat "announced that its Board of Directors is evaluating strategic alternatives for the NauticStar business. The Board is considering a wide range of available alternatives to maximize shareholder value, including a potential sale of NauticStar's assets, with the intention of exiting the NauticStar business."

17:42 EDT OraSure appoints Kenneth McGrath as CFO - OraSure (OSUR) has appointed Kenneth McGrath as the company's new CFO, effective August 8. McGrath replaces Scott Gleason, who has served as the interim CFO and will continue in his role leading investor relations and corporate communications going forward. McGrath joined Quest Diagnostics (DGX) in February 2014 and most recently served as VP in finance.

17:31 EDT Algoma Steel reports fire on one of its coal conveyors - Algoma Steel Group announced that a fire occurred on August on one of its coal conveyors that supplies coal to two of its three coke batteries. No one was injured in this event. Algoma produces its own coke from three production units, and supplements with purchased coke from various suppliers. Iron and steelmaking operations are expected to continue in the normal course while the damage is repaired, as the Company can continue to produce coke at a reduced rate, and anticipates it has sufficient coke inventory and supply contracts for purchased coke to support steelmaking operations. The Company is continuing to assess the damage and complete repair plans.

17:27 EDT Riot Blockchain to delay filing 10-Q - The company states: "The Registrant is required to perform goodwill impairment assessments at least annually, and more frequently if indicators of impairment exist. In response to recent adverse changes in business climate, including decreases in the price of Bitcoin and increased volatility of equity markets, as evidenced by declines in the market price of the Registrant's securities, those of its peers, and major market indices, the Registrant has determined to perform an impairment assessment of its carrying value of recorded goodwill. The complexity of analyzing the impact of various global macroeconomic and geopolitical factors, such as the ongoing war in Ukraine, global logistics slowdowns, and recent significant inflationary pressures, on the Registrant's carrying value of recorded goodwill is causing a delay in finalizing the Registrant's accounting determinations, which must be concluded before the Registrant's interim financial statements to be included in the Quarterly Report can be completed."

17:24 EDT Nutanix to reduce global headcount by approximately 270 employees - On August 9, Nutanix announced a plan to reduce its global headcount by approximately 270 employees, which represents approximately 4% of the company's total employees, following a review of its business structure and after taking other cost-cutting measures to reduce expenses. The headcount reduction is part of the company's ongoing efforts to drive towards profitable growth. The company expects to complete substantially all of the headcount reduction by the end of the fiscal quarter ending October 31. As a result of the headcount reduction, the company currently estimates that it will incur a pre-tax charge in the range of $20M-$25M during the fiscal quarter ending October 31, consisting of one-time severance and other termination benefit costs, all of which are expected to result in future cash expenditures.

17:20 EDT Brink's Eaton appoints Kurt McMaken as CFO - The Brink's Company (BCO) announced that Kurt McMaken will join the company on August 24 as executive vice president and CFO. Ron Domanico, who has served as the company's FO officer since 2016, will remain at Brink's to support the transition. He will continue as president of Brink's Capital, the entity that helps provide funding for the company's digital cash retail solutions, and lead the company's recently established Sustainability Program until his planned retirement in June 2023. McMaken will join the executive leadership team and report to Eubanks. McMaken joins Brink's from Eaton Corporation (ETN), an intelligent power management company, where he served in a number of financial and management positions since 2001. He most recently served as senior vice president, operations finance and transformation, and as an officer of the company and member of the CEO's senior leadership committee. During his tenure, he also served as president of the company's operations in Europe, Middle East and Africa, which he oversaw from a post in Morges, Switzerland.

17:14 EDT Parsons director buys $1.45M in common stock - In a regulatory filing, Parsons disclosed that its director George Ball bought 35K shares of common stock in a total transaction size of $1.45M.

17:08 EDT Cricut board authorizes share buyback for up to $50M

16:58 EDT Coinbase drops nearly 5% to below $84 after Q2 results

16:56 EDT Roblox drops 13% to $41.29 after Q2 results miss estimates

16:55 EDT Trade Desk jumps 16% to $63.50 after Q3 revenue guidance beats estimates

16:52 EDT Danimer Scientific backs FY22 adjusted EBITDA view ($45M)-($35M) - The company now expects full year capital expenditures to be in the range of $175 million to $185 million, inclusive of capitalized interest and internal labor and overhead, with a year-end cash balance in excess of $60 million. Looking beyond 2022, the company expects its PHA-based revenues to drive a significant increase in the company's overall profitability. The company remains confident in its ability to execute against its objectives with a prudent focus on profitability and cash management.

16:50 EDT Paysign announces changes to board of directors - Paysign announced that Daniel Spence, co-founder and member of the Paysign Board of Directors, has tendered his resignation as a member of the board, effective August 8, 2022. The company also announced that Matthew Lanford, President and COO, has been appointed as a member of the board, replacing Spence.

16:48 EDT Accenture acquires YSC Consulting, terms not disclosed - Accenture has acquired YSC Consulting, a CEO advisory and leadership consultancy that helps organizations align leadership strategies with their business goals to achieve transformational change. The acquisition strengthens Accenture's capabilities to advise the CEO, C-Suite, and Board with solutions to boost performance and build leadership teams for the future. Terms of the transaction were not disclosed. "Leaders must meet new expectations to win the hearts and minds of employees and customers in a rapidly changing world," said Christie Smith, global lead of Talent & Organization / Human Potential at Accenture. "Successful business leaders thrive through the application of meaningful purpose and the use of technology to lead with accuracy, speed, empathy, and transparency. It's at the cross-section of these values where Accenture and YSC Consulting truly align. We look forward to coming together and helping clients maximize their impact and carve a successful future steered by modern leadership."

16:47 EDT Digital Media Solutions, Seekr announce new strategic partnership - Seekr, an internet technology and content evaluation company, and Digital Media Solutions, Inc. announced a multi-year agreement to support Seekr's media strategy, revenue and advertising operations across its global search advertising platform and vertical content sponsorships. The alliance will accelerate the build-out and monetization of new Seekr verticals in concert with expanding its global audience and reach. "DMS has the expertise to support our advertising needs and the proven ability to innovate and expand, making them the perfect partner for Seekr," said Pat Condo, Seekr founder and CEO. "The partnership represents an important step forward in Seekr's vision to provide an online experience with tools that support information transparency, connecting people with what they seek, rather than what they are served."

16:46 EDT Endeavor Group to sell Diamond Baseball Holdings to Silver Lake - Endeavor Group Holdings, Inc. announced it has entered into a definitive agreement to sell its Professional Development League (PDL) business, Diamond Baseball Holdings (DBH), to Silver Lake, the global leader in technology investing. Diamond Baseball Holdings has been operating under Endeavor in its mission to bring value to local Minor League Clubs affiliated with Major League Baseball through professional management, best practices, innovation and investment. To date, Diamond Baseball Holdings has acquired 10 Clubs: Iowa Cubs (Triple-A affiliate of the Chicago Cubs); Memphis Redbirds (Triple-A affiliate of the St. Louis Cardinals); Scranton/Wilkes Barre RailRiders (Triple-A affiliate of the New York Yankees); Hudson Valley Renegades (High-A affiliate of the New York Yankees); San Jose Giants (Single-A affiliate of the San Francisco Giants); Gwinnett Stripers (Triple-A affiliate of the Atlanta Braves); Mississippi Braves (Double-A affiliate of the Atlanta Braves); Rome Braves (High-A affiliate of the Atlanta Braves); Augusta GreenJackets (Single-A affiliate of the Atlanta Braves); Oklahoma City Dodgers (Triple-A affiliate of the Los Angeles Dodgers). Under Silver Lake's ownership, Pat Battle and Peter Freund will continue to lead the PDL business as Executive Chairman and Chief Executive Officer of Diamond Baseball Holdings, respectively. The transaction is expected to close in the fourth quarter of 2022, subject to applicable regulatory consents and approvals and the satisfaction of certain customary closing conditions.

16:45 EDT Owens & Minor announces strategic collaboration with Allina Health - Owens & Minor announced their renewed partnership and a new strategic collaboration to create a unique integrated service model for supply chain resiliency. The integrated service model is an evolution of the 20-year partnership between Allina Health and Owens & Minor. At the heart of the model is an integrated service center that will serve as the hub and central command for supply chain operations, combining communications, fulfillment, inventory management and distribution into an end-to-end solution built specifically for the needs of Allina Health's hospital and clinical care network, including its 6,000 associated and employed physicians. "Allina Health believes that deepening our successful relationship with Owens & Minor will elevate our ability to ensure that our providers and clinical staff have the products they need, when they need them," said Thomas M. Lubotsky, Vice President of Supply Chain, Allina Health. "Further combining our collective strengths is key to our vision for exploring creative, innovative ways to improve our supply chain operations. We are excited by what this new phase of our 20-year strategic partnership with Owens & Minor will bring."

16:44 EDT Sandstorm's shareholders approve acquisition of Nomad Royalty - Sandstorm Gold (SAND) announced that at its special meeting of shareholders held earlier today, the Company's shareholders approved the resolution for the issuance of common shares of Sandstorm in connection with the arrangement whereby Sandstorm will acquire all of the issued and outstanding common shares of Nomad Royalty Company (NSR) at an exchange ratio of 1.21 Sandstorm Shares for each common share of Nomad. The Resolution was approved by approximately 99% of votes cast by Sandstorm shareholders at the Meeting. Detailed voting results for the Resolution are as follows:

16:36 EDT Virtus Investment reports preliminary AUM $163B as of July 31 - In addition, the company provided services to $3.1B of other fee-earning assets, which are not included in assets under management.

16:35 EDT Shift announces details of merger with CarLotz - Under the terms of the merger agreement, CarLotz shareholders are expected to receive approximately 0.692158 shares of Shift common stock for each share of CarLotz common stock. The actual exchange ratio will be adjusted at the closing based on Shift's issued and outstanding shares prior to the effective time of the merger, relative to the fully diluted CarLotz shares prior to the effective time of the merger. Based on the expected exchange ratio, upon the closing of the merger Shift's then-current equity holders will own approximately 52.9% of the combined company, and CarLotz's then-current equity holders will own approximately 47.1% of the combined company, calculated on a fully diluted basis. We expect the transaction to close in Q4 2022 subject to CarLotz's and Shift's shareholders' approvals and other customary and regulatory approvals. Shift is advised by Centerview Partners and Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC. as financial advisor and Jenner & Block LLP as legal counsel. CarLotz is advised by William Blair & Company as financial advisor and Freshfields Bruckhaus Deringer LLP as legal counsel.

16:34 EDT Shift Technologies appoints Jeff Clementz as CEO, effective September 1 - Shift's Board of Directors announced the appointment of current Shift President Jeff Clementz as CEO effective September 1. After nearly nine years in the role of CEO, Co-founder George Arison will be stepping down and remaining in his role of Chairman of the Board of Directors. Clementz will continue to serve as CEO of Shift following its merger with CarLotz.

16:33 EDT Shift Technologies announces stock for stock merger with CarLotz - Shift (SFT) announced it has entered into a definitive agreement to merge with CarLotz (LOTZ), a used vehicle consignment business, in a stock-for-stock merger. Upon closing, the go-forward business plan is expected to be fully funded to profitability by the cash position of the combined company.

16:28 EDT TransAct: Delay caused by change in accounting principle

16:28 EDT Invesco reports preliminary AUM $1.45T as of July 31 - An increase of 4.2% versus previous month-end. The firm experienced net long-term outflows of $5.2B in the month.

16:26 EDT Coinbase backs FY22 transaction expenses view of low 20% range - Sees FY22 average MTUs 7M-9M. Sees FY22 sales and marketing expenses $500M-$600M.

16:25 EDT Coinbase sees Q3 MTUs lower than Q2 - Sees Q3 total trading volume lower compared to Q2. Sees Q3 subscription and services revenue modestly higher compared to Q2.

16:23 EDT Coinbase says 'soft crypto market conditions from Q2 continuing into Q3' - Coinbase said in its quarterly letter: "Soft crypto market conditions from Q2 are continuing into Q3 and are reflected in our Q3 outlook. July MTUs declined to 8.0 million. Accordingly, we expect MTUs to be lower in Q3 compared to Q2 and for a higher portion of MTUs to be non-investing users compared to investing users compared to Q2. July trading volume of $51 billion reflected a continuation of the trends discussed above. If these trends continue, we believe Q3 will be lower compared to Q2. We expect Subscription and services revenue to be modestly higher in Q3 compared to Q2, primarily driven by increases in Interest Income. We anticipate transaction expenses to be in the low 20% range."

16:20 EDT Berkeley Lights sees FY22 revenue in line with FY21 revenue - Consensus is for FY22 revenue $100.91M. The company said, "Berkeley Lights now expects FY22 revenue to be approximately in line with FY21 revenue as the Company works to realign the business around its new strategic objectives."

16:12 EDT WM Technology names Douglas Francis executive chair - WM Technology also announced that the Company's Board of Directors has appointed WM Technology's co-founder Douglas Francis as Executive Chair. In this newly created role, Mr. Francis will provide additional oversight and directly engage with management in developing the Company's strategy and driving its execution. Francis said, "As one of the leading technology and software providers to the cannabis industry, Weedmaps is ideally positioned to professionalize the cannabis marketplace, creating value for consumers and compelling returns for our shareholders. I have been a part of the Company for over 14 years and am excited to again be directly involved with management as we deliver on our mission to power a transparent and inclusive global cannabis economy."

16:11 EDT WM Technology sees ending FY22 with positive adjusted EBITDA - The company said, "Based on current business trends and conditions, we are planning against an outlook where total revenue is flat-to-down in the mid-single digit percent area on a year-over-year basis for the second half, which implies a low double-digit percent growth rate for the full year 2022. We expect to end the year with positive Adjusted EBITDA for the full year 2022."

16:09 EDT H&R Block announces new $1.25B share repurchase authorization - The company announced that the Board of Directors approved a new share repurchase authorization of $1.25B, effective through fiscal year 2025.

16:08 EDT Revance sees funding into 2024 - Revance expects 2022 GAAP operating expenses to be $375 million to $400 million and non-GAAP operating expenses, which exclude costs of revenue, depreciation, amortization and stock-based compensation to be $260 million to $280 million. Revance expects 2022 non-GAAP research and development expense to be $100 million to $110 million. With the current cash, cash equivalents and short-term investments of $233.8 million, management projects that the company is funded into 2024, with an additional $100 million in notes available under the company's note purchase agreement, subject to the FDA approval of DaxibotulinumtoxinA for Injection for glabellar lines.

15:59 EDT Surgalign Holdings trading halted, volatility trading pause

15:08 EDT Aretech announces countersuit filed against Bioventus company - Aretech responded today to a patent infringement complaint previously filed by Bioness, a subsidiary of Bioventus. On August 8, Aretech filed a countersuit against Bioness, Inc, alleging that Bioness engaged in fraud to secure patents from the U.S. Patent and Trademark Office and is now pursuing sham litigation against Aretech. "In addition, Aretech has alleged claims of antitrust violations, patent invalidity, non-infringement, unenforceability, and intentional interference with business expectancy," the company announced.

14:36 EDT Real Good Food Company Inc trading resumes

14:33 EDT chairman of OP Bancorp Brian Choi purchased $437K in company shares - Chairman of OP Bancorp Brian Choi Brian purchased 36,682 shares of company stock at $11.91 on August 8, for a total transaction amount of $436,758. .

14:24 EDT FDA finds nitrosamine impurity in Merck diabetes drug Januvia - The FDA said it recently became aware of a nitrosamine impurity, Nitroso-STG-19, in certain samples of Merck's Januvia, also known as sitagliptin, a medicine used to treat type 2 diabetes mellitus. "To avoid a shortage and help ensure patients have access to an adequate supply of the medicine, FDA will not object to the temporary distribution of sitagliptin containing NTTP above the acceptable intake limit of 37 ng per day, and up to 246.7 ng per day," the agency said in a statement. Sitagliptin is a prescription drug used to control high blood sugar in patients with type 2 diabetes mellitus. The FDA recommends prescribers continue to use sitagliptin "when clinically appropriate to prevent a gap in patient treatment." Reference Link

14:09 EDT Amphastar slides as company provides CRL update alongside earnings - Shares of Amphastar (AMPH) are under pressure after the company reported second quarter results and discussed the complete response letter for its AMP-002 ANDA filing as well as the CRL for its AMP-015 ANDA. RESULTS: Amphastar reported net revenues of $123.5M for the second quarter and adjusted EPS of 39c, with consensus at $127.48M and 40c, respectively. CRL UPDATE: During Amphastar's earnings conference call, the company said, according to a call transcript: "Regarding our regulatory efforts, I would like to bring our discussion towards our AMP-002 ANDA filing, to which we received a CRL last month. We believe the issues raised are addressable and will be fully responded to this quarter. Therefore, we anticipate the GDUFA action date for this filing in the first quarter of 2022. While this news is certainly not one we would have liked to receive, we remain confident with AMP-002's future commercial prospects as it remains without any generic... To our AMP-015 ANDA filing, teriparatide, and the CRL received in June, we anticipate filing our response in the fourth quarter this year. Likewise, we remain confident that the inquiries made for this filing are entirely achievable." PRICE ACTION: In Tuesday afternoon trading, shares of Amphastar have dropped nearly 16% to $31.86.

13:35 EDT Chipotle workers in NY City to receive approximately $20M in settlement - New York City Mayor Eric Adams and New York City Department of Consumer and Worker Protection, DCWP, Commissioner Vilda Vera Mayuga today announced a settlement with Chipotle Mexican Grill, Inc. to deliver up to approximately $20M in compensation to approximately 13,000 workers who experienced violations of their right to predictable schedules and paid sick leave under the Fair Workweek and Paid Safe and Sick Leave laws. Chipotle will also pay $1 million in civil penalties. The agreement is the result of DCWP's multiyear investigation into complaints filed by 160 Chipotle employees and by 32BJ SEIU. DCWP's investigation found major violations of laws that affected all Chipotle employees in New York City. The settlement with Chipotle is the largest fair workweek settlement nationwide and the largest worker protection settlement in New York City history. "Restaurants and fast food outlets are a critical part of our economy and our daily life here in New York City, but they cannot exist without the hard-working people who are cooking and serving and delivering our food," said Mayor Adams. "Today's settlement with Chipotle is not only a victory for workers by securing up to $20M in relief for approximately 13,000 workers, but also sends a strong message, as the largest worker protection settlement in New York City history, that we won't stand by when workers' rights are violated. I thank 32BJ SEIU for helping uncover these violations and the Department of Consumer and Worker Protection for getting justice for these workers." Reference Link

12:17 EDT MiX Telematics announces collaboration with Hino Trucks - MiX Telematics (MIXT) announced that it is collaborating with Hino Trucks' Edge to become an authorized Hino data services partner.This collaboration will provide MiX customers in North America that operate Hino trucks with rich data sets, informing intelligent decision-making regarding vehicle maintenance, safety, efficiency, and compliance, the company said in a statement. "The future of commercial vehicle telematics lies in successful OEM integrations," says Charles Tasker, Chief Operating Officer at MiX Telematics. "MiX is rapidly accelerating working with leading vehicle OEMs to ensure clients can easily access rich data needed to optimize fleet and driver safety." Hino is owned by Toyota (TM).

12:00 EDT American Vanguard falls -19.5% - American Vanguard is down -19.5%, or -$4.72 to $19.45.

12:00 EDT Direxion Daily Semiconductor Bear 3X Shares rises 14.7% - Direxion Daily Semiconductor Bear 3X Shares is up 14.7%, or $5.48 to $42.86.

12:00 EDT Nielsen rises 21.4% - Nielsen is up 21.4%, or $4.86 to $27.57.

11:43 EDT Osisko Development cautions investors to 'not rely upon' third party commentary - Osisko Development responds to commentary by third parties in relation to its Tintic project. The company said, "The third parties attended at the Company's premises and interviewed Company personnel. Following the interview, Osisko Development reviewed and authorized for release an abridged version of the interview. Contrary to the Company's guidance, the third parties proceeded to release an unabridged version of the interview that includes commentary by the third parties that the Company did not authorize. The Company is committed to the highest standards of public disclosure. The Company cautions that investors should not rely upon third party commentary in respect of the Company and its assets, and should instead rely upon disclosure made by the Company. The Tintic Project, while viewed by the Company as an exciting opportunity for further exploration with potential for development, remains as described in the public disclosure of the Company, in particular its news releases of June 10, 2022, June 28, 2022, and July 7, 2022."

11:33 EDT Applied DNA Sciences awarded extension of health services contract with CUNY - Applied DNA Sciences announced that The City University of New York has extended its health services contract for COVID-19 testing and vaccine policy management with the Company's wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, for 12 months through July 2023 and at the prior contract terms. ADCL's COVID-19 testing volumes, including the CUNY contract, fueled the Company's record fiscal 2021 revenues and consecutive quarterly record revenues in the first half of fiscal 2022 ended March 31, 2022.

11:30 EDT Zhong Yang Financial Group Ltd trading resumes

11:20 EDT Zhong Yang Financial Group Ltd trading halted, volatility trading pause

11:11 EDT Wag Labs announces closing of business combination with CHW Acquisition - Wag Labs announced the closing of its business combination with CHW Acquisition Corporation. The Business Combination was approved on July 28, 2022, by CHW Acquisition Corporation's stockholders. Upon the completion of the business combination, CHW changed its name to Wag! Group Co. and beginning August 10, 2022, the Company's common stock and warrants are expected to begin trading under the new ticker symbols, "PET" and "PETWW", respectively, on the Nasdaq. Wag!'s Chief Executive Officer, Garrett Smallwood, and the current Wag! management team will continue to lead the combined entity. In addition, Wag! is reserving up to 300,000 shares of common stock for its previously announced Wag! Community Shares Program to benefit eligible pet caregivers and domestic pet nonprofit organizations.

11:05 EDT Boeing reports 130 commercial airplane gross orders, 26 deliveries in July - In a post on its corporate site, Boeing reported 130 commercial airplane gross orders for July and 26 airplane deliveries in July. Reference Link

11:02 EDT Jack Henry to acquire PayRailz, terms not disclosed - Jack Henry & Associates announced that it has entered into a definitive agreement to acquire Payrailz, adding the company's next-generation digital payment capabilities, including real-time person-to-person payments, to Jack Henry's payments ecosystem. Based in Glastonbury, Conn., Payrailz provides cloud-native, API-first, AI-enabled consumer and commercial digital payment solutions and experiences that enable money to be moved in the moment of need, and banks and credit unions to successfully compete with industry disruptors. This acquisition enhances Jack Henry's payments-as-a-service strategy, which is a natural extension of its commitment to open banking and the ability to enable embedded finance and embedded fintech. Jack Henry supports the growing demand for PaaS with a virtual payments hub that consolidates money-moving solutions and supports numerous payment channels and types. Payrailz strategically complements this hub with next-generation capabilities for consumer and commercial bill pay, real-time person-to-person, account-to-account, business-to-customer payments, and more. Financial details and terms of the definitive purchase agreement were not disclosed. The acquisition is expected to close August 31, 2022.

10:44 EDT GoodRx rallies after saying grocer issue recently addressed - GoodRx said in last night's earnings letter, "We are pleased to share that the grocer issue we discussed on our first quarter earnings call was very recently addressed. As communication is rolled out to the grocery chain's pharmacists, we expect GoodRx discounts to be consistently welcomed at the point of sale. We are delighted that our consumers can enjoy the prescription access and affordability benefits of GoodRx at the grocery chain, who we value as a partner. Despite this very recent positive development, we do not anticipate a meaningful volume or revenue lift in the third quarter based on the rollout timeline of relevant communications to the grocery chain's pharmacies, new user adoption and returning user levels. We expect third quarter revenue to be approximately $185 million. This assumes the grocer issue has an estimated impact of $35 million to $40 million on third quarter prescription transactions revenue. We're expecting a greater impact quarter-over-quarter because the effect on the second quarter gradually increased as the quarter developed, whereas we started the third quarter facing a significant impact. In addition to the effect of the grocer issue on prescription transactions revenue, we expect our recent consumer engagement efforts, which we will discuss on our second quarter earnings call, to negatively impact prescription transactions revenue by approximately $5 million in the third quarter." Shares of GoodRx are up 6% to $8.20 in morning trading.

10:28 EDT Verona Pharma surges after ensifentrine meets endpoint in COPD study - Verona Pharma shares are sharply higher in New York trading after the company announced earlier its top-line Phase 3 ENHANCE-2 trial results evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease, or COPD. The ENHANCE-2 trial has successfully met its primary endpoint, as well as secondary endpoints demonstrating improvements in lung function, and significantly reduced the rate and risk of COPD exacerbations, the company announced. The company reported placebo corrected, change from baseline in average FEV1 area under the curve 0-12 hours post dose at week 12 was 94 mL for ensifentrine. Reported placebo corrected, increase in peak FEV1 of 146 mL 0-4 hours post dose at week 12. Daily symptoms and QOL as measured by E-RS Total Score and SGRQ Total Score in the ensifentrine group improved from baseline to greater than the minimal clinically important difference of -2 units and -4 units, respectively, at week 24. Improvements in these measures were seen as early as 6 weeks and showed continued improvement at 12 and 24 weeks, numerically exceeding placebo at each measurement. Statistical significance was not achieved due to improvements observed in the placebo group over time. David Zaccardelli, Pharm. D., Verona Pharma's President and Chief Executive Officer, said: "We are very pleased by the successful outcome of our ENHANCE-2 study and remain committed to bringing ensifentrine to COPD patients as quickly as possible. These data, along with results from our ongoing Phase 3 trial, ENHANCE-1, which is on track to be reported around the end of 2022, if similarly positive, are expected to support the submission of a New Drug Application to the US Food and Drug Administration in the first half of 2023. We want to thank all the patients and investigators for their participation in the trial to advance ensifentrine as a potential new therapy for the treatment of COPD." Verona Pharma plans to release additional information from ENHANCE-2 at upcoming scientific conferences. Near 10:30 am ET, Verona shares are up $5.20, or 75%, to $12.15.

10:11 EDT Clearside Biomedical jumps following financing pact with HealthCare Royalty - Shares of Clearside Biomedical (CLSD) are on the rise on Tuesday after the company announced a non-dilutive financing agreement with HealthCare Royalty, supporting progression of CLS-AX clinical program. Alongside its second quarter results, Clearside Biomedical said it had entered into a Royalty Interest Purchase and Sale Agreement with HealthCare Royalty Partners, which may provide the company up to $65 million in non-dilutive funding to support ongoing clinical development of Clearside's pipeline, and pursuant to which HealthCare Royalty Partners will receive all royalties and milestone payments due to Clearside from XIPERE and certain SCS Microinjector license agreements, subject to a cap of 2.5 times the total purchase price paid by HealthCare Royalty under the agreement. The cap may be increased under certain circumstances. In Tuesday morning trading, shares of Clearside have gained about 9% to $1.78.

10:09 EDT Groupon: Layoffs include payroll and nonpayroll reductions - Comments taken from Q2 earnings conference call.

10:00 EDT Trinseo falls -16.0% - Trinseo is down -16.0%, or -$5.63 to $29.49.

10:00 EDT American Vanguard falls -22.0% - American Vanguard is down -22.0%, or -$5.32 to $18.85.

10:00 EDT AMTD Digital rises 23.2% - AMTD Digital is up 23.2%, or $94.00 to $499.00.

09:51 EDT AMTD Digital Inc trading resumes

09:48 EDT Ralph Lauren expects further pressure on gross margins near term - Cites cost inflation. Expects gross margin contraction in 1H23 and then expansion in 2H23. Sees inventory more in line with sales by end of FY23. Says continuing to gain market share.

09:47 EDT 3D Systems falls -15.3% - 3D Systems is down -15.3%, or -$2.02 to $11.22.

09:47 EDT Solo Brands rises 14.2% - Solo Brands is up 14.2%, or 78c to $6.28.

09:47 EDT Nielsen rises 21.2% - Nielsen is up 21.2%, or $4.81 to $27.52.

09:41 EDT D-Wave Quantum Inc trading resumes

09:38 EDT MEGL Stock trading resumes

09:35 EDT News Corp trading resumes

09:33 EDT Oportun Financial trading halted, volatility trading pause

09:32 EDT BetMGM becomes official sportsbook partner of NFL in Canada - BetMGM announced a multi-year partnership extension with the National Football League, becoming one of the League's Official Sportsbook Partners in Canada. BetMGM was among the first operators to go live in Ontario, having launched its online sports betting and iGaming platforms in April 2022. As a part of the newly expanded relationship, BetMGM now has the rights to use official NFL marks in Canada and advertise on NFL-operated digital platforms throughout the region. Additionally, BetMGM will offer Canadian customers access to exclusive NFL experiences.

09:22 EDT WISeKey implementing post-quantum algorithms - During the last two years, WISeKey has made substantial progress in developing post-quantum resistant algorithms by establishing strategic R&D partnerships with MINES Saint-Etienne Research Institute, aiming to help the international community find cryptography algorithms that will resist future quantum computing based cyber-attacks. The WISeKey's team of experts is working with several NIST's candidates for the MS600X Common Criteria products: Crystals-Kyber for key exchange mechanism, and Crystals-Dilithium for signatures. The partnership is focusing into the practical implementation aspects for both algorithms, considering physical side-channel attack and deep learning process. This work completes the implementation of NTRU and ROLLO algorithms that the team has already studied, paving the way of a complete post-quantum cryptography toolbox.

09:18 EDT Aytu BioPharma announces pricing of public offering - Aytu BioPharma announced the pricing of its underwritten public offering of 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants to purchase 23,255,814 shares of its common stock. The shares of common stockand the accompanying Common Warrants will be issued separately but can only be purchased together in this Offering. The combined public offering price for each share of common stock and accompanying Common Warrant is $0.43, and the combined offering price for each pre-funded warrant and accompanying Common Warrant is $0.429, which equals the public offering price per share of the common stock and accompanying Common Warrant, less the $0.001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the Offering are expected to be approximately $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Aytu. All of the securities in the Offering will be sold by Aytu. The Offering is expected to close on August 11, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome, for growth of the company's commercial business, and for working capital and general corporate purposes. Cantor and Canaccord Genuity are acting as the joint bookrunners for the Offering.

09:17 EDT Medicenna Therapeutics announces pricing of $20M public offering - Medicenna Therapeutics announced that it has priced its previously-announced marketed underwritten public offering of 13,333,334 units of the Company in the Canada and in the United States at a price to the public of US$1.50 per Unit. The gross proceeds to the Company from the Offering are expected to be approximately $20 million, before deducting underwriting discounts and commission and other expenses. Each Unit will be comprised of one common share and one common share purchase warrant. Each Warrant entitles the holder thereof to purchase one common share at a price of US$1.85 per common share, subject to adjustment in certain events, during a period of 60 months following the date of the closing of the Offering. Guggenheim Securities, LLC is acting as sole book-running manager for the Offering. Bloom Burton Securities Inc. is acting as co-manager for the Offering. The Offering is expected to close on or around August 11, 2022, subject to the satisfaction of customary closing conditions, including the listing of the common shares issuable pursuant to the Offering on the Toronto Stock Exchange and the Nasdaq Stock Market and any approvals of each exchange. The Company plans to use the net proceeds of the Offering primarily to fund the clinical development of MDNA11, the pre-clinical development of a BiSKIT candidate, working capital and for general corporate purposes.

09:16 EDT Nova Vision Acquisition announces additional contribution to trust account - Nova Vision Acquisition announced that Nova Pulsar Holdings Limited, the Company's initial public offering sponsor, has deposited into the Company's trust account an aggregate of $575,000 in order to extend the period of time the Company has to complete a business combination for an additional three months period, from August 10, 2022 to November 10, 2022. The Company issued a promissory note to Sponsor with a principal amount equal to the amount deposited. The promissory note bears no interest and is convertible into the Company's units at a price of $10.00 per unit at the closing of a business combination by the Company. The purpose of the extension is to provide time for the Company to complete a business combination.

09:15 EDT Rockley Photonics gets first commercial order for Rockley Bioptx band - Rockley Photonics Holdings announced that it has signed a supply agreement outlining the customer's initial purchase commitment for 2023 and received the first commercial purchase order for its non-invasive biomarker sensing wristbands from a global healthcare technology provider. The Bioptx Baseline devices included in this order will employ Rockley's biosensing technology, a complete end-to-end solution that enables the non-invasive, continuous, and near-real-time monitoring of multiple biomarkers. The initial units are expected to ship in Q4 2022, which could put Rockley's ground-breaking biosensing technology on the wrists of end-users by the end of 2022. The Rockley Bioptx band represents a new class of wearable biosensing devices, with enhanced health monitoring capabilities and a flexible design that's appropriate for a multitude of applications and uses, such as professional healthcare or general health and wellness. The form and function of the device allow it to be worn on the wrist or other locations on the body, depending on the use case and physical requirements. In addition to a versatile form factor, the Bioptx band features a flexible hardware design that will support a range of software stacks that can be customized to address the specific needs of various customers. The software can be further adjusted to optimize battery life for extended use or maximize performance for intensive duty cycles.

09:12 EDT Tabula Rasa HealthCare shareholder sends open letter to its board - Indaba Capital, which is the largest shareholder of Tabula Rasa HealthCare, with an ownership interest of approximately 25% of the company's outstanding shares, issued an open letter to the independent members of the company's board of directors. The letter said, "As you know, Indaba is Tabula Rasa's largest shareholder by a significant margin and holds more than seven times the number of shares owned by the current Board. While we prefer to have a constructive, private dialogue with you, your apparent disregard for sound corporate governance and unwillingness to substantively engage with us forces us to once again make our concerns public. Today, we are writing to demand answers to the following questions: Why are you refusing to directly engage with us despite our substantial shareholdings, valid concerns and willingness to collaborate on a necessary Board refresh? Why did you feel it was appropriate to dilute shareholders in order to issue more equity to Chief Executive Officer and Chairman Dr. Calvin H. Knowlton, President and Director Dr. Orsula V. Knowlton and their relatives - especially given shareholders' resounding "withhold" votes against the Knowltons and opposition to the executive compensation proposal at the 2022 Annual Meeting of Shareholders (the "Annual Meeting")? Why are you unwilling to reduce the boardroom influence of the husband-and-wife management team by demanding the resignations of the Knowltons from the Board? You approved a term sheet from Indaba that provided for their resignations earlier in the summer. While Mr. Tunstall's and Ms. Beckwith's apparent intransigence can be explained by their conflicts and historical interlocks to the Knowltons, we cannot understand why the rest of you continue to ignore the highly problematic governance issues plaguing the Company today. Your silence and unwillingness to take action force us - and presumably other shareholders - to conclude you may not take your service on this Board seriously. In our view, independent directors who want to disassociate themselves from egregious governance practices and protect all shareholders would retain their own legal counsel to either commence an independent investigation of the Knowltons' various self-serving acts or add new independent directors who will have the courage to do so. We hope you finally engage in good faith with us and take actions that benefit all shareholders, instead of acting in conflict with the shareholders to whom you owe your fiduciary duties. With respect to your decision to approve more dilutive equity compensation that benefits the Knowltons, we remain confounded. The decision calls into question your independence given the overwhelming investor rebuke of the Knowltons at this year's Annual Meeting, whereat approximately three out of four shareholders voted down the egregious compensation package put forth for the Company's named executive officers. This year's generous award also comes on the heels of the Knowltons' value-destructive share pledging transactions. Shareholders are now being forced to suffer approximately 3% dilution despite the Company's share price being down more than 65% year-to-date, the vast majority of shareholders voting against the Company's say-on-pay vote at this year's Annual Meeting and the Knowltons already having received millions of dollars in equity grants in the preceding years. This is all in the face of both of the Knowltons receiving a majority of "withhold" votes cast at the Annual Meeting by unaffiliated stockholders, which we understand to be exceedingly rare. We certainly hope you are not accommodating the Knowltons because they may be in financial distress after recently being forced to sell a majority of their Tabula Rasa shares under pledging arrangements. We suspect this selling may have been undertaken to finance the development of a home that has been described as a "44,000+ square foot mega mansion" with "6 bedrooms, 12 bathrooms, grand double staircase, elevator, formal living & dining rooms, gourmet kitchen, breakfast room, family room, 2-story library, 2-story great room/ballroom, home theater, golf simulator, wine cellar, indoor pool, garage and more."2 We believe more disclosure is required to explain why this was the right time to essentially take from aggrieved shareholders and employees and give to the Knowltons and their relatives - and we intend to do everything it takes to claw back these egregious grants on behalf of all stockholders. Prioritizing and perpetuating nepotism at a publicly traded company is a sure way to lose favor with employees, partners, customers and shareholders alike. To put it bluntly, we believe your actions are unjustifiably putting the Company's business and its stakeholders at serious risk. Lastly, you should explain why you backtracked on your support for having the Knowltons step down from the Board. We were informed that the independent directors voted in a unanimous manner to approve our term sheet, which included the resignations of the Knowltons from the Board. You must recognize the absurdity of the Company's corporate governance and conflicts of interest. We note that if the Knowltons will not voluntarily resign from the Board, they will be required to step off the Board if they are terminated from their employment with the Company - thereby allowing the independent directors to achieve the very result they previously supported. Backtracking on a previously approved term sheet is a very curious move that raises questions about where your allegiance really lies. We expect to receive prompt answers through either direct engagement or a public disclosure. We are going to continue shining light on your apparent prioritization and protection of the Knowltons, their relatives and their friends - in an increasingly detailed manner - until the status quo changes. We can assure you that, as the Company's largest shareholder, we will not tire in this pursuit and the longer this journey takes, the endgame is no less inevitable and the risk each of you bear as individuals will likely only increase."

09:10 EDT American Resources receives commitment of $4.9M in federal credits - American Resources announced in addition to its previously announced preliminarily approval for the issuance of, and a volume cap allocation for $45,000,000 of private activity, Solid Waste Disposal Facility Revenue Bonds, the Company has received an allocation commitment totaling $4,900,000 of federal New Markets Tax Credits for the Company's Wyoming County Coal complex located near the town of Oceana, West Virginia. Created in 2000 the New Markets Tax Credit Program is administered by the US Department of Treasury through the Community Development Financial Institutions Fund. The program has supported over 1,254 allocations in its 16-year history and allows for patient and adaptive capital to flow to underserved communities. It is expected that the net benefit to WCC will be $1,500,000 with a closing concurrent to or after the closing of the Tax-Exempt Industrial Development Bonds. On December 16, 2021, the West Virginia Economic Development Authority approved a resolution preliminarily approving the issuance of up to $45,000,000 of Tax-Exempt Solid Waste Disposal Facility Revenue Bonds, Series 2022 on behalf of the Company's wholly-owned subsidiary, Wyoming County Coal LLC. The Company is progressing on the issuance of such bonds with its recently transferred underwriter Hilltop Securities. The Company expects the $45 million Tax-Exempt Industrial Development Bonds from West Virginia and the NTMC to close within the next 90 days. The WCC complex is strategically located within one of the last substantial mid-volatile metallurgical carbon deposits and, with direct access to the Norfolk Southern Railway, provides favorable transportation logistics to the United States' east coast ports. Additionally, WCC is surrounded by a number of high-value metallurgical carbon reserves and remining sites that would otherwise be considered "stranded" without access to the WCC processing and logistics complex. The Company's focus will initially be to bring the two new underground mines into production via a "walking super section" mine plan which will produce an estimated 55,000 tons of carbon per month, with further expansion potential as the mines are developed. American Resources will also look to upgrade and expand WCC's carbon processing plant's capacity, from its current 350 tons per hour rate, to approximately 700 ton per hour, while also incorporating the Company's innovative "capture" and "process" technology which will enable the facility to capture and process critical and rare earth elements from new carbon production and carbon-based waste sources to produce rare earth and critical element concentrates. The REE and CE concentrates produced will be transported to the Company's Indiana facility for further purification and isolation.

09:09 EDT Movano announces completion of study to assess SpO2 - Movano announces the successful completion of a study with the University of California San Francisco, or UCSF, to assess the accuracy of the Movano Ring's blood oxygen saturation, or SpO2, and heart rate data. With results that exceeded the requirements of the industry standard used by FDA for evaluating SpO2 devices, this successful study is a promising step toward the company's goal to provide medically-validated data to consumers and healthcare professionals. The study was conducted on seven subjects of mixed genders and ethnicities and followed the same protocol that we expect will be required by the FDA for the submission. Wearing a Movano Ring prototype and reference devices within a controlled environment, each participant's oxygen levels were driven down to as low as 70% and then back up to 100% to test the accuracy of Movano's device during mild, moderate and severe hypoxia. The prototype also measured heart rate during this time and participants' heart rate varied from 60 to 120 beats per minute as they were being deprived of oxygen.

09:08 EDT Emcor acquires Gaston Electrica in Norwood, MA, terms undisclosed - EMCOR Group announced that it has acquired Gaston Electrica full service electrical construction contractor headquartered in Norwood, MA. Terms of the transaction were not disclosed. Dan Fitzgibbons, President and CEO of EMCOR's Electrical Construction Services Segment commented, "We are pleased to expand our footprint in the Northeast with the addition of the Gaston team. This group brings important capability and expertise in servicing many of EMCOR's core end markets, including life sciences facilities and data centers. With one of the most experienced executive and field management teams in the electrical construction industry, Gaston will further broaden and enhance the service offerings EMCOR provides to its customers in the Greater Boston area."

09:07 EDT Sage Group launches Sage Payroll - Sage announced the Canadian release of Sage Payroll, which integrates accounting, payroll and HR functions into a single unified platform with Sage Accounting. The new, cloud-first solution from Sage is uniquely positioned to enable small businesses, HR and accounting teams, to manage payroll and employee data in one platform with employee self-serve features, to help their business flow.

09:06 EDT Creative Realities rolls out Creator X tool - Creative Realities announced the rollout of Creator X, a new tool within the ReflectView digital signage software suite that allows users to design content directly within the platform. The new feature can be accessed in Reflect Xperience, an optimized way to create and manage content all within the existing digital signage platform. Creator X allows for seamless content layout creation and design tools that can be launched from anywhere in the world - without the need for tech-proficient third-party creative teams. The tool boasts an easy-to-use designer platform with basic features such as text and image editing, video components, template creation and dimension customizations.

09:05 EDT Aerojet Rocketdyne's Arkansas site opens new facility - Aerojet Rocketdyne's Camden, Arkansas, site has opened a new facility to integrate solid rocket motor manufacturing activities, improving operational efficiency, increasing production capacity, reducing costs, and providing for even safer operations. "We are building upon our proud legacy of providing reliable propulsion by investing and expanding to support future military readiness," said Eileen Drake, Aerojet Rocketdyne CEO and president. "This $13.5 million facility is a testament to our commitment to providing innovative, affordable propulsion to support both today's defense programs and those of tomorrow." The new 51,000 square foot building consolidates multiple manufacturing activities under one roof and adds advanced equipment, including modern tool-up bays, dedicated propellant casting and oven areas, and upgraded X-ray systems, all emphasizing a safe production process. The facility results in a reduction in the need to transport motors across the site during manufacturing by more than 90%.

09:05 EDT Kintara receives a Study May Proceed letter from the FDA for REM-001 study - Kintara Therapeutics announced that it has received a Study May Proceed letter from the FDA to begin its 15 patient study evaluating REM-001 Photodynamic Therapy, or PDT, for the treatment of Cutaneous Metastatic Breast Cancer, or CMBC. This study is intended to aid in the design of a planned phase 3 registrational study. PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of oxygen that induces local tumor cell death. The planned clinical study is expected to enroll 15 patients with CMBC that is refractory or not eligible for radiotherapy or surgery. The study will evaluate cutaneous tumor response using standardized and calibrated 3D digital photography.

09:03 EDT Republic First Bancorp appoints Harry Madonna as Interim CEO - Republic First Bancorp, the parent company of Republic First Bank d/b/a Republic Bank, announced that founder and former CEO and Board Chair, Harry D. Madonna, Esquire has been named Interim CEO of the Company, effective immediately. He will also hold the role of Executive Chair of the Company's Board of Directors. These changes come on the heels of the departure of Vernon W. Hill, Jr. as CEO, who, together with Barry Spevak, resigned from the boards of the Company and the Bank today. Given the resignation of Mr. Spevak from the Boards of the Bank and the Company, Andrew B. Cohen, an accomplished financial manager, has been named as the third member of the Audit Committee. Madonna has more than 30 years of banking experience, founding Republic Bank in 1988. He has served as President and CEO of Republic First Bancorp, Republic Bank's holding company since 2001, Chair from 1988 to 2016, Interim Board Chair commencing in July of 2022, and President of the Bank from 2001 to 2010. From 2002 to 2005, he was of counsel to Spector Gadon & Rosen, PC, and a partner of Blank Rome LLP from 1980 to 2001.

09:02 EDT Arthur J. Gallagher acquires Evergreen Insurance Managers, no terms - Arthur J. Gallagher & Co. announced that its U.S. wholesale brokerage, binding authority and programs division, Risk Placement Services, has acquired Hillsboro, Oregon-based Evergreen Insurance Managers Inc. Terms of the transaction were not disclosed. Founded in 2006, Evergreen Insurance Managers is a wholesale insurance broker and managing general agency offering commercial insurance solutions for a wide variety of industries.

09:01 EDT BRP reports malicious cybersecurity activity - On Monday, August 8, BRP determined that it was the target of malicious cybersecurity activity. BRP took immediate measures to contain the situation. The Company has activated its internal network of IT professionals and retained the services of cybersecurity experts to assist in securing its systems and support its internal investigation. Operations have been suspended temporarily, which may delay certain transactions with customers and suppliers.

08:58 EDT Jaguar Health issued patent for treating chemotherapy-induced diarrhea - Jaguar Health announced that the United States Patent and Trademark Office on July 19, 2022 issued a new U.S. patent to Napo Pharmaceuticals, the company's wholly owned subsidiary, for methods for treating diarrhea, as well as the pain, abdominal discomfort and other symptoms associated with diarrhea, in patients with an inhibitor of chloride-ion transport such as Napo's crofelemer drug product.

08:55 EDT SKYX Platforms' SkyPlug outlet for lighting and fan approved by ANSI / NEMA - SKYX Platforms announced that its universal safe installation specifications for plug & play ceiling outlet for lighting and fan products has been officially voted on and approved by ANSI / NEMA, the U.S. standardization organizations for the standardization of the SKYX safe weight-bearing plug and outlet/receptacle for ceilings .The American National Standards Institute is the leading U.S. standards approval organization, whose standards are regularly specified by most architects and engineers for U.S. residential and commercial buildings to ensure safety, quality and reliability. The National Electrical Manufacturers Association is a standards-developing organization that promotes the standardization of major U.S. electrical products for manufacturers. The achievement of an ANSI / NEMA vote approval is a lengthy and rigorous process, widely considered to be very difficult to achieve. Examples of other products that are standardized include the wall outlet, GFCI bathroom outlet and other key products that are included in every home in the U.S. The standardization of the SKYX plug & play weight-bearing plug and outlet/receptacle for ceilings by ANSI/NEMA will universally provide SKYX's product specifications to manufacturers to help save lives, time and money for both professionals and consumers, enabling them to install light fixtures and ceiling fans with a safe plug & play installation in just minutes, if not seconds

08:55 EDT Endo expects pre-arranged filing under Chapter 11 'imminently' - As of June 30, 2022, the company had approximately $1.2 billion in unrestricted cash; $8.1 billion of debt; and a net debt to adjusted EBITDA ratio of 5.6. These amounts reflect the company's payment of $35 million to acquire 6 sterile injectable product candidates and a $30 million upfront payment related to a Phase 3 injectable compound for the treatment of osteoarthritis knee pain. Second-quarter 2022 net cash used in operating activities was $133 million compared to $155 million provided by operating activities during the second-quarter 2021. This change was primarily attributable to decreased revenues. The company remains in constructive negotiations with an ad hoc group of first lien creditors, among other parties. In light of the progress to date, the company expects that these negotiations will likely result in a pre-arranged filing under Chapter 11 of the U.S. Bankruptcy Code by Endo International plc and substantially all of its subsidiaries, which could occur imminently.

08:51 EDT American Resources gets $4.9M in federal credits, provides update on WV bond - American Resources announced in addition to its previously announced preliminarily approval for the issuance of, and a volume cap allocation for $45,000,000 of private activity, Solid Waste Disposal Facility Revenue Bonds, the Company has received an allocation commitment totaling $4,900,000 of federal New Markets Tax Credits for the Company's Wyoming County Coal complex located near the town of Oceana, West Virginia. Kirk Taylor, Chief Financial Officer of American Resources Corporation commented, "We are excited to see the continued support of our innovative business model by both the federal and state governments. By securing additional patient and non-dilutive capital, we can focus on bringing new-age growth to the state of West Virginia that matches the needs of our modern and transitioning electrified economy. The integration of rare earth and critical element processing with premium carbon extraction is a first for the industry and enables us to showcase our full suite of patented technologies to better leverage the region's broader resource base. Our innovative approach allows us to produce both premium, mid vol carbon for steel and alloy metal production while capturing and processing critical and rare earth concentrates resulting in a more environmentally-safe refuse. We believe our WCC complex will help usher in the next generation of natural resource capabilities to the region, its workforce and communities while also helping fuel our domestic demand for rare earth and critical elements."

08:47 EDT Aon plc names Mindy Simon as COO, James Platt as Chief Digital Officer - Aon plc (AON) announced that the firm's COO James Platt will move into the new role of Chief Digital Officer overseeing Digital Client Solutions and Mindy Simon will join the firm as COO leading Aon Business Services. Simon will join the firm on October 10 from Conagra Brands (CAG), where she most recently served as Chief Information Officer and oversaw global business services, information technology and cyber security.

08:43 EDT Ondas expects Q3 operating expenses $8M-$8.5M - Ondas is reaffirming its financial and operational outlook for 2022. Ongoing investments in market expansion and deeper penetration of select verticals are expected to support commercial adoption of Ondas Networks' FullMAX wireless platform and additional installations of AR's Scout System in 2022.Ondas Networks will continue to focus on the greenfield 900 MHz network with North American Class I Rails. Ondas Networks expects bookings and revenue growth to accelerate as the Company moves through the year with a target of $20 million in product bookings in 2022. In addition, Ondas Networks expects to secure $3.5 million in product development programs, including the European locomotive program announced in June. In the third quarter of 2022, Ondas Networks intends to continue building product inventory and increasing internal human resources to meet an expected increase in product demand for both North American Rail and International markets. Also, the Company expects American Robotics to secure and announce additional Franchise customers for the Scout System in 2022. Throughout 2022, AR will continue to build inventory to meet this customer demand. In parallel, American Robotics will continue to invest in and scale its field service operations to create capacity to handle expanded drone deployments with existing customers and to support new customer activity. Scout System deployments will focus on a select group of blue-chip customers in the oil & gas, mining, bulk materials, and rail sectors in the coming quarters. AR is targeting 30 Scout Systems(TM) installed across 10 customer accounts by year-end 2022, and its objective is to secure one or more customer reorders to begin fleet expansion. In parallel, American Robotics will continue to invest in data analytics products targeted at these customers and their respective markets. We are working to secure at least one formal partnership with a customer in 2022. Given the anticipated addition of Airobotics in the coming months, the Company's cash operating expenses are now expected to be approximately $8.0 - $8.5 million in the third quarter. Cash operating expenses exclude non-cash expenses, such as stock-based compensation and amortization of intangible assets and goodwill. The Company expects bookings and revenue growth to fluctuate from quarter-to-quarter given the timing of development activity in front of the targeted commercial rollout for the Rail 900 MHz network, the multiple development projects planned with Siemens Mobility and the integration and scaling of American Robotics business.

08:40 EDT Veru announces presentation of phase 3 study of Sabizabulin - Veru announced that the Phase 3 COVID-19 study results of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome, ARDS, were presented at the 11th International Conference on Emerging Infectious Diseases, ICEID, on August 8, 2022. Presentation Highlights: Sabizabulin is an oral, novel microtubule disruptor that has dual antiviral and anti-inflammatory activity. In a double-blind, multicenter, and placebo-controlled Phase 3 clinical study evaluating sabizabulin 9 mg versus placebo in 204 hospitalized moderate-severe COVID-19 patients who were at high risk for ARDS and death. For the primary endpoint which was all cause mortality by Day 60, a clinically meaningful and statistically significant 55.2% relative reduction in deaths was observed in the intent-to-treat population. Sabizabulin treatment also resulted in a 43% relative reduction in days in ICU, 49% relative reduction in days on mechanical ventilation, and 26% relative reduction in days in hospital vs placebo. "The large reduction in deaths in this high-risk population was confirmed in the Phase 3 COVID-19 study. We are currently engaged with the FDA, EMA, MHRA, and regulatory agencies in other countries to seek emergency authorization and/or expedited reviews. If authorized, we have scaled up manufacturing to meet the demands of this summer's COVID-19 surge as well as the seasonal surges that are expected in fall and winter," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru.

08:40 EDT Genasys receives $2.2M LRAD order - Genasys announced a $2.2M commercial security order for certain domestic data centers of an international company.

08:39 EDT T2 Biosystems to explore potential to develop test for Monkeypox virus - T2 Biosystems announced plans to explore the potential to develop a rapid molecular diagnostic test for detection of the monkeypox virus, including technical and commercial feasibility. "Our team has demonstrated the scientific expertise to develop new tests on our proprietary platform, including direct-from-blood and swab tests, and we believe the development of a molecular diagnostic test for the monkeypox virus is possible on our platform," stated John Sperzel, Chairman and CEO of T2Biosystems. "Given the urgent nature of the monkeypox virus, and the potential for global transmission, we have communicated with the FDA and CDC and we are exploring the potential to develop and commercialize a test for the monkeypox virus."

08:37 EDT Investor makes proposal to acquire AIkido for $8 per share in cash - Shalom Auerbach, a significant stockholder of AIkido Pharma beneficially owning approximately 3.8% of its common stock, today announced that he has sent a letter proposing to acquire the Company for $8.00 per share in cash. Shalom Auerbach wrote, "In prior public letters to the AIKI Board of Directors and Company stockholders, I laid out significant concerns regarding the Company's performance, direction and governance, which concerns are shared by many other stockholders. Most recently, I called upon the Board to take action immediately to prevent further destruction of stockholder value at AIKI, including by commencing an orderly process to sell the Company's assets and distribute capital to stockholders. Disappointingly, the Board has refused to genuinely engage with me and appears set on continuing to pursue the Company's "diversification" strategy by spending stockholder funds to start three new businesses unrelated to the Company's historical biotechnology business... Today, I am prepared to stand behind that conviction and am proposing to acquire 100% of the outstanding shares of common stock of AIKI that I do not already own for $8.00 per share in cash. This proposal to buy AIKI represents a 31% premium to the Company's most recent closing share price on August 8, 2022,1 and would provide substantial and immediate cash value for the Company's stockholders...The transaction would be subject to the following conditions: (i) receipt of required Board and stockholder approvals; (ii) receipt of any required governmental and third-party approvals; (iii) limited confirmatory due diligence; and (iv) the negotiation and execution of a definitive merger agreement containing terms and conditions customary for a transaction of this type and size... I am prepared to engage meaningfully and constructively with the Board to achieve a successful transaction in a quick and efficient manner. I strongly believe that this proposal is the best opportunity for AIKI stockholders to achieve certain value for their shares on an expeditious basis. I also would support a decision by the Company to commence a full sale process with a plan to distribute the proceeds to stockholders, as I urged the Board to do in my prior letters."

08:36 EDT Cemtrex's Vicon hires Haim Shain as SVP, product managment - Cemtrex announced that its subsidiary, Vicon Industries, has appointed of Haim Shain as Senior Vice President of Product Management. In this new role, Shain will oversee the strategy and implementation behind Vicon's expanding product line, from their award-winning Roughneck surveillance cameras and VAX access control system, to their centralized video management platform, Valerus VMS. Under his leadership, Vicon's product teams will further drive innovation, including cloud-based video management and AI-enabled video analytics solutions. A dynamic and accomplished leader in the surveillance industry, Shain has 17 years of experience directing product management at leading companies, including LenelS2, FLIR Systems and DVTEL.

08:35 EDT HCA Healthcare to collaborate with Johnson & Johnson to address industry issues - HCA Healthcare (HCA) announced that it will collaborate with Johnson & Johnson (JNJ) to address healthcare industry issues. The companies initially will focus on improving health equity, enhancing nursing support, and improving patient outcomes: HCA Healthcare and Johnson & Johnson will collaborate on a scalable program to improve health outcomes through early-stage lung cancer detection for the Black community. HCA Healthcare, which has more than 93,000 nurses in its system, and Johnson & Johnson have a long-standing commitment to advocating for and supporting nurses. The two healthcare leaders will work together to incorporate Johnson & Johnson's nursing resources within HCA Healthcare and its affiliate Galen College of Nursing. The companies will work together on health equity issues focused on educational programming, training and other programs that elevate and support nurses with a goal of enriching the nursing experience and skillsets and improving patient outcomes. HCA Healthcare, through its HCA Healthcare Research Institute, and Johnson & Johnson will collaborate on cardiovascular health initiatives including a retrospective analysis of patients who suffer from heart arrhythmia, as well as research to understand the role digital health technology plays in impacting clinical outcomes for patients with Coronary Artery Disease and Peripheral Artery Disease diseases.

08:35 EDT L.B. Foster provides update on the market outlook - "While recessionary conditions persist and are in some ways expanding, the Company expects that many of its businesses may continue to directly benefit from infrastructure investment activity, including funding benefits from U.S. Infrastructure Investment and Jobs Act ("IIJA") passed in November 2021. While order and backlog levels in our Precast segment have benefited from the Great American Outdoors Act passed in 2020, we have not yet seen significant business activity from the IIJA. We anticipate that IIJA-related funding will be processed by the various agencies during 2022 and moving into 2023. We should then see quotations and orders increasing as a result of such activity, with related revenue realized in 2023 and beyond. The present inflationary environment in labor and raw materials continues to pressure margins across the business, and the Company has initiated and will continue to consider future mitigation actions, including price increases for its products and services. In addition, the Company is taking proactive steps to manage disruptions in raw materials, labor, supply chains, service partner resources, and lingering COVID-19 related effects to mitigate their adverse impact on its operations and results as much as possible. While such conditions and the related impacts are expected to continue to improve throughout 2022 and beyond, they could persist throughout the remainder of 2022 and possibly longer. Despite these challenges, with the proceeds from the Piling and Track Components divestitures, coupled with the additional flexibility and capacity resulting from the amendment and extension of our credit agreement completed in August 2021, the Company believes it has the resources available to fund its operations and execute on organic and acquisitive growth opportunities in 2022 and beyond," the company said.

08:34 EDT Bristow Group placed order for five BETA Technologies' ALIA-250 aircraft - Bristow Group has placed a firm order for five electrically powered vertical take-off and landing ALIA-250 aircraft manufactured by electric aviation company BETA Technologies. Bristow will also have the option to purchase an additional 50 ALIA aircraft. The ALIA will have a maximum range of 250 nautical miles and is designed to carry 1,400 lbs of payload or can carry six people including a pilot. With a 50-foot wingspan and a carbon-fiber fuselage, the aircraft uses a single distributed direct-electric propulsion system and has four horizontally mounted rotors that provide vertical lift and a single propeller in the rear to propel the aircraft forward.

08:33 EDT Mullen Automotive reports $99M in cash on hand as of August 8 - Mullen Automotive announces preliminary third-quarter results. In addition to recent highlights and successes for the Company and its EV programs, Mullen is in a strong financial position, with approximately $99 million in cash and cash equivalents on hand as of Aug. 8, 2022. Financial Highlights: Asset growth of 391%; Asset growth was primarily from cash from financing activities along with increased property and equipment. Positive working capital $27,656,446; Working capital was a positive variance due to the paydowns in current notes and cash received from financing activities. $318 million in financial commitments ; The committed capital positions Mullen for growth over the remainder of 2022 and 2023. Change in debt -77%; The 77% debt reduction minimizes debt overhang problem and implies that equity holders can invest in a company positioned for growth and sound financial performance. 281% increase in R&D spending; Company has increased its spending for R&D, which primarily relates to engineering costs for the Mullen FIVE and Mullen EV cargo van programs. "It's an exciting and pivotal time for Mullen as we continue to experience exceptional growth," said David Michery, CEO and chairman of Mullen Automotive. "We've been focused on expanding our capital positions, resources and efforts in all key business areas, and we are really seeing it come together with our recent expansions and successes."

08:32 EDT Relmada Therapeutics receives FDA fast track designation for REL-107 - Relmada Therapeutics announced that the FDA has granted Fast Track designation to REL-1017, the Company's novel NMDA receptor, or NMDAR, channel blocker, as a monotherapy for the treatment major depressive disorder, or MDD. Relmada's late-stage development program for REL-1017 includes Reliance III, an ongoing monotherapy registrational Phase 3 trial. In addition, Reliance I and Reliance II are two ongoing Phase 3 sister two-arm, placebo-controlled, pivotal studies evaluating REL-1017 as a potential adjunctive treatment for MDD. The Reliance development program also includes Reliance-OLS, the long-term open-label safety study that is enrolling rollover participants from all three pivotal studies, as well as de novo participants.

08:31 EDT Heritage Global to sell Covid-19 testing site - Heritage Global, a subsidiary of Heritage Global, opened online bidding for a Covid-19 testing site. Auction lots will begin closing tomorrow, August 10. The auction sale features large quantities of liquid handlers, PCR machines, centrifuges, freezers, hoods, and related lab assets, many of which are gently or never used and still in their original packaging. The auction catalog is currently posted with equipment photos, complete descriptions and links to the auction registration where prospective buyers can place their bids.

08:29 EDT Charles River gets EMA approval to produce allogeneic cell therapy drug products - Charles River announced it has received regulatory approval, in the form of Good Manufacturing Practice, or GMP, certification, to commercially produce allogeneic cell therapy drug products for distribution in Europe, from the European Medicines Agency, or EMA. The approval follows an inspection by the cell and gene therapy experts from the Italian inspectorate, Agenzia Italiana del Farmaco, performed on the EMA's behalf.

08:28 EDT Mindset Pharma expects to launch one or more drug candidates over next year - Mindset Pharma issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset, which read in part, " Mindset's overarching strategy since inception has been to methodically apply state-of-art drug discovery approaches in medicinal chemistry and pharmacology to known psychedelic compounds to create the next-generation of psychedelic drug candidates to better serve patients in need. In the last 6 months, our focused efforts have begun to deliver an impressive and growing series of world class innovations, partnerships, and feedback reinforcing our patent portfolio position, which collectively differentiates and establishes Mindset as the premiere biotech company working in the psychedelic space today...I am extremely encouraged with the progress we've made so far in bringing novel mental health therapies one step closer to patients in need. Mindset has successfully developed a leading portfolio of next generation NCEs, patent pending processes to synthesize first generation psychedelic drug candidates efficiently and cost-effectively, and a novel intranasal delivery system to improve the overall pharmacokinetic properties of first- and second-generation psychedelic drug candidates. Over the next twelve months, we expect to launch one or more of our novel drug candidates to in-human clinical trials. Additionally, we will look to find more synergistic strategic partners that share our vision to continue to advance our growing pipeline of new drugs. With a strong team and alliances in place to expedite our time-to-market and de-risk our drug development programs, we will continue to work hard on the research and development required to unlock new discoveries so that we can provide better insight into the pharmacological potential of psychedelic medicines, both for the industry at large and, one day, to help patients overcome a range of psychiatric and neurological disorders."

08:26 EDT Post Holdings announces debt-for-equity exchange, offering of BellRing stock - Post Holdings announced an underwritten offering of 14,800,000 shares of common stock of BellRing Brands. The offering shares, currently owned by Post, were sold by J.P. Morgan Securities LLC, Barclays Bank Plc, Citicorp North America, Inc., Goldman Sachs Lending Partners LLC and Morgan Stanley & Co. or their designees in connection with the entry by the Company into an Exchange Agreement, dated August 8, 2022, with the funding incremental term loan lenders. Under the Exchange Agreement, the Company will transfer 14,800,000 of its shares of common stock of BellRing to the funding incremental term loan lenders to repay and retire approximately $340 million in aggregate principal amount of the Company's previously announced incremental term loan, excluding any accrued interest, which will be paid with cash off of the Company's balance sheet. Immediately after giving effect to the Debt-for-Equity Exchange, the Company will retain 4,597,339 shares of common stock of BellRing. The offering is being made pursuant to a registration statement filed by BellRing with the U.S. Securities and Exchange Commission. BellRing is not selling any shares of common stock of BellRing and will not receive any proceeds from the sale of the offering shares in the offering. The offering is expected to close on August 11, 2022, subject to customary closing conditions. J.P. Morgan Securities LLC, Barclays Capital Inc., Morgan Stanley & Co. LLC, Citigroup Global Markets Inc. and Goldman Sachs & Co. LLC are acting as joint lead book-runners and representatives of the underwriters for the offering.

08:23 EDT Nogin enters agreement with United Sports Brands - Branded Online has announced a multi-brand CaaS agreement with United Sports Brands. Nogin's all-in-one software platform is a cloud-based, headless, eCommerce environment, purpose-built for brands selling direct-to-consumer and through online channel partners. As part of a three-year agreement, USB brands will plug into Intelligent Commerce to deliver world class eCommerce to their consumers without all the cost, complexity, time, and risk of building and managing their own online stores. In addition to Nogin's full stack eCommerce platform, USB brands receive advanced proprietary modules such as the Company's Customer Data Platform, Social Commerce, and Predictive Automation technologies, features that help enhance sales growth and improve profits. In addition, Nogin's ongoing upgrades and optimizations to these features help ensure that brands will never need to re-platform their eCommerce operations to remain on the cutting-edge.

08:23 EDT Alimera announces reimbursement of uveitis indication granted for ILUVIEN - Alimera Sciences announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has been granted reimbursement for ILUVIEN 0.19 mg sustained release intravitreal implant for non-infectious uveitis affecting the posterior segment in Portugal. Reimbursement was granted by the National Authority of Medicines and Health Products, INFARMED, with no change to the current label. "This summer has been a productive one for expanding availability of our non-infectious uveitis indication in our International Segment with it soon to be accessible to patients in all of our direct markets in addition to our key distributor markets," said Rick Eiswirth, President and Chief Executive Officer of Alimera. "We are looking forward to the third quarter launches in Portugal and France to make ILUVIEN available for patients suffering from this persistent inflammatory condition and give physicians in these countries a better tool to help their patients see better, longer, with fewer injections."

08:21 EDT Splash Beverage CEO sees 'strong foundation' to support business plan - Splash Beverage Group issued a letter to shareholders from Robert Nistico, Chairman and CEO of Splash Beverage Group, which read in part, " On behalf of Splash's Board of Directors, our senior management team and employees, we are delighted to have you as shareholders and as valued members of our corporate family. As we prepare to release Q2 results in the next couple of weeks, I wanted to take a few moments and share with you some of the important developments that have occurred at Splash Beverage Group since the beginning of the year and as we proceed in the coming months. No update would be complete without reiterating the transformative announcement we made on November 17, 2021, in which we signed a distribution agreement for TapouT, Copa di Vino and Pulpoloco with AB ONE. AB ONE, of course is owned by AB-InBev, the corporate owner of Budweiser and the agreement represented our single largest distribution deal to date. This agreement is extremely important to Splash because with one agreement, we achieved a level of recognition and distribution ability in the industry that might have taken years to achieve on our own, if ever. With that recognition came the credibility of being associated with one of the blue-chip names in the beverage distribution business. And from that moment we've been growing and building momentum. ..Distribution is the key to the beverage business. Securing these arrangements is all about relationships and hard work. Our relationships with key distributors like AB-ONE and Kalil Bottlers helped open doors, and our team's ability to execute have and will continue to do the rest. Some of the impact from these announcements was felt in our first quarter financial results reported back in May when we reported an 86% increase in year over year revenues, but most of these agreements and authorizations took place over the course of the first half of 2022, so we have not really begun to see the financial impact of these relationships. We also recently announced our plans to acquire an 80% interest in Pulpoloco. We've been the exclusive importer of Pulpoloco to the US since 2021 and we've overseen a dramatic increase in the growth of the brand and most recently, a commitment in 7-11 in approximately a third of the US to start. At the same time, we're seeing an incredible increase in societal interest in all things renewable and biodegradable. Pulpoloco is packaged in a highly innovative, ecofriendly paper can called the CartoCan. This unique packaging, itself made from sustainable wood fiber, generates less greenhouse-emissions during production and presents an overall lower carbon footprint. This not only enhances the value of Pulpoloco's products but opens the possibility for myriad other uses as the eco-friendly product becomes more widely recognized. Acquiring the majority interest in this business makes strong business sense. We see unique opportunities for each of our brands, each one reflecting positive consumer trends in their respective segments. TapouT is tapping into a growing market for isotonic beverages that offer a healthier list of ingredients. Flavored tequila is showing growth in the spirits category and in the single serve wine segment, Copa Di Vino is proving to be a breakout product with consumers. And of course, the opportunity afforded by bio-degradable paper cans has the potential to be a complete game changer. So, we feel we're in all the right categories at all the right times. We believe we have a strong foundation to support our business plan. We have a management team with deep experience in the beverage industry, a robust portfolio of brands that are aligned with the latest in consumer demands, a growth strategy that is firing on all cylinders as evidenced by the 8-month string of distribution and authorization announcements, and we have access to the capital we need to grow. "

08:19 EDT Blue Water announces $10M private placement - Blue Water Vaccines announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase of 3,683,280 shares of common stock in a private placement priced at-the-market under Nasdaq rules. The Company will also issue to the investors unregistered preferred investment options to purchase up to an aggregate of 4,972,428 shares of common stock. The purchase price for one share of common stock and one investment option to purchase one share of common stock is $2.715. The investment options will have an exercise price of $2.546 per share, will be exercisable immediately upon issuance, and will have a term equal to five years following the issuance date. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the private placement are expected to be approximately $10 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the private placement for the research and development of its pipeline as well as for working capital and other general corporate purposes. The Company's current cash position including the expected gross proceeds from this private placement is approximately $30.3 million. The private placement is expected to close on or about August 11, 2022, subject to the satisfaction of customary closing conditions.

08:17 EDT NV5 Global awarded $8M contract expansion - NV5 Global announced that it has been awarded a contract for approximately $8M over three years to support electrical transmission and distribution for a prominent Southwest utility. The agreement expands NV5's relationship with the utility service provider to include engineering design of electrical substations, overhead power lines, and underground transmission and distribution assets. NV5 will also deliver testing and commissioning services of existing assets as well as consulting and design services for new commercial, industrial, and residential developments.

08:11 EDT Ovid Therapeutics sees cash runway into 2025 - Cash, cash equivalents and marketable securities as of June 30, 2022 was $152.4 million.

08:07 EDT Clear Secure to launch at Milwaukee Mitchell International Airport - Clear Secure announced it is launching its expedited security screening lanes at Milwaukee Mitchell International Airport. MKE is Clear's first airport in Wisconsin and 45th across the U.S. The launch is expected to create 34 jobs and generate more than $2.6M in local economic activity.

08:06 EDT Prelude Therapeutics expects cash to fund operations into 2H24 - Cash, cash equivalents, and marketable securities as of June 30, 2022, were $246.3 million. Prelude anticipates that its existing cash, cash equivalents and marketable securities will fund Prelude's operations into the second half of 2024.

08:01 EDT Orion Energy secures $4.2M in LED lighting retrofit projects - Orion Energy Systems announced it has secured contracts totaling $4.2M to retrofit two manufacturing facilities for a major automotive manufacturer. Orion expects to complete the retrofit projects during its fiscal 2023 third and fourth quarters. Mike Altschaefl, Orion's Board Chair and CEO, commented, "We are pleased to extend our long term partnership with this leading global auto producer to extend their workplace safety and energy efficiency initiatives across two additional North American manufacturing facilities. We are encouraged to see projects like these, which were delayed for some time, to be authorized and funded for completion."

07:59 EDT Spirit Realty increases quarterly dividend 3.9% to 66.3c per share - Spirit Realty announced that its board of directors declared an increase in the company's quarterly common stock cash dividend on August 8 from 63.8c per share to 66.3c per share, an increase of 3.9%, representing a new annualized rate of $2.65 per share. Stockholders of record as of Friday, September 30 will receive the cash dividend on Friday, October 14.

07:57 EDT Revival Gold provides exploration update - Revival Gold provides an update on exploration at the Beartrack-Arnett Gold Project located in Lemhi County, Idaho, USA. On August 8th, 2022, Revival Gold completed the second of two core holes for a total of 1,450 meters drilled at the Joss target this season. The two drill holes, BT22-241D and BT22-242D, were designed to test the down-dip potential of high-grade gold mineralization at Joss. "Core logging indicates that we've hit the target zone at Joss. Assay results are expected next month and offer the potential to confirm a significant depth extension to Joss, where previous drilling has returned high-grade intercepts in 18 drill holes over a 1 km trend. In the meantime, drilling continues with activity expected to increase as rigs become available and conditions allow," said Hugh Agro, President & CEO. A second drill rig is expected to arrive at Beartrack-Arnett in September to initiate approximately 2,000 meters of core drilling at Haidee as conditions allow. If feasible, Revival Gold will mobilize a third drill rig to complete approximately 3,000 meters of previously planned reverse circulation exploration drilling to test several early-stage near surface oxide gold exploration opportunities at Beartrack-Arnett.

07:55 EDT Pacira, NFLA team up to educate athletes on non-opioid pain management - The National Football League Alumni Association, NFLA, and Pacira BioSciences announced the launch of their partnership to increase awareness of the availability and benefits of non-opioid options to manage acute and chronic pain, including postsurgical pain and knee osteoarthritis, OA. The program seeks to educate retired players, NFLA chapter presidents and staff, youth sports organizations including Play 60, Pop Warner, and the Amateur Athletic Union about the importance of non-opioid pain management options that can reduce or eliminate the need for opioids, which can be associated with unwanted and potentially severe side effects. The partnership will include educational opportunities at NFLA state and local chapter events, as well as national tournaments throughout the year including the Super Bowl, Pro Bowl, Super Bowl of Golf, the Red, White, & Blue Celebrity Golf Classic, and the NFLA Super Bowl Pro-Am. "Partnering with NFLA gives Pacira a unique and engaging way to inform athletes at every stage of play about the non-opioid options available to treat both acute and chronic pain," said Dave Stack, Chief Executive Officer and Chairman of Pacira BioSciences, Inc. "Our work with respected partners like the NFLA allows us to help support player safety while raising awareness about pain management options that can play a critical role in fighting the opioid crisis." The program will launch this fall with various events and activations concluding in May 2025.

07:54 EDT Evergy to purchase 199 MW Persimmon Creek Wind Farm in Oklahoma, no terms - Evergy and a partnership between Scout Clean Energy and Elawan Energy announced today that Evergy will purchase the 199-megawatt Persimmon Creek Wind Farm in western Oklahoma for a purchase price of about $25M. The renewable energy from this wind farm will serve customers in the Evergy Missouri West service area. "Evergy continues to tap into the Midwest's affordable renewable energy resources to serve our customers," said David Campbell, Evergy president and CEO. "Expanding our portfolio of renewable generation positions us to ensure customers receive the long-term benefits of these assets." Persimmon Creek Wind Farm achieved commercial operation in 2018 with 80 General Electric turbines across 17,000 acres in Dewey, Ellis and Woodward counties in Oklahoma. The acquisition of Persimmon Creek Wind Farm, which is expected to close by early 2023, remains subject to closing conditions, including regulatory approvals.

07:52 EDT KemPharm appoints Ochsner as VP, Investor Relations, Corporate Communications - KemPharm (KMPH) announced the appointment of Nichol Ochsner to the role of Vice President, VP, Investor Relations and Corporate Communications. In this newly created position, Ochsner will be responsible for driving external awareness of KemPharm's value proposition, including ongoing relations with the Company's shareholders, covering analysts and prospective investors. Prior to joining KemPharm, Ochsner served as Executive Vice President of Investor Relations and Corporate Communications with Statera Biopharma (STAB).

07:50 EDT Siga Technologies announces BARDA exercise of procurement options - SIGA Technologies announced the exercise of procurement options under its 75A50118C00019 contract with the U.S. Department of Health and Human Services for the delivery to the U.S. government of intravenous formulation of TPOXX treatment courses valued at approximately $26M. These option exercises represent the first procurement option exercises for IV TPOXX under the 19C contract. Product deliveries of IV TPOXX in connection with these contract options are targeted for 2023. IV TPOXX is an important option for those who are unable to swallow. "These option exercises for the procurement of IV formulation of TPOXX as well as the funding of a post-marketing field study for IV TPOXX highlight the growing importance of a broad-based response to the substantial risks posed by the orthopox family of viruses, including smallpox and monkeypox," said Phil Gomez, CEO of SIGA. "The exercised options are among many procurement options under the 19C contract that remain to be exercised and, as such, we will continue to coordinate with the U.S. government toward future procurements of oral TPOXX and IV TPOXX." The procurement options, which were exercised by the Biomedical Advanced Research and Development Authority, part of the office of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, include the manufacture of bulk drug substance and the use of such substance to manufacture and deliver final drug product of IV TPOXX.

07:49 EDT CleanSpark acquires plug-in ready bitcoin mining facility for $16.2M - CleanSpark announced it has entered into a definitive agreement to acquire an active bitcoin mining facility located in Washington, Georgia, for $16.2M. The Company has also purchased approximately 3,400 of the latest generation Antminer S19 series of machines for approximately $8.9 million. These machines, already operating at the acquired site, will add over 340 petahashes per second of computing power. The Company will fill the balance of the 36 MW with machines already paid for and on hand. The site has exclusive rights to an additional 50 MW of power, making the site scalable to 86 MW. "We are excited to expand our footprint in Georgia," said Zach Bradford, CleanSpark's CEO. "The market has been preparing all summer for consolidation, and we are pleased to be on the acquiring side. Our focus on sustainability and maximizing value for our stakeholders have put us in a unique position to take advantage of the unprecedented opportunities that the current market has created. We are especially excited to be working with the citizens of Washington, GA, who have been so welcoming to us. We look forward to maintaining and growing jobs and infrastructure at our new campus in Washington." The site is CleanSpark's third clean-energy campus in Georgia, with other locations in College Park and Norcross. It draws power predominantly from low-carbon sources, such as nuclear energy.

07:48 EDT Akoustis ships second 5G mobile filter design in its new wafer-level-package - Akoustis Technologies announced that it has completed the second design iteration of a 5G mobile filter and shipped samples to its first XBAW mobile foundry customer. The new filter samples utilize Akoustis' newly developed wafer-level-package technology and target mobile applications including 5G smartphones and other devices. This engagement continues to progress towards one or more design wins, and Akoustis is targeting production ramp in the second half of calendar 2023. This is expected to be the second 5G mobile XBAW customer in production following the expected launch of the first tier-1 customer expected in late calendar 2022/early calendar 2023. Jeff Shealy, founder and CEO of Akoustis, stated, "We continue to make tremendous progress in our 5G mobile efforts driven by our leading XBAW technology and our growing success in the development of wafer-level-packaging technology in our New York manufacturing facility." Shealy, continued, "Mobile remains our largest opportunity by volume and revenue, and Akoustis is in a great position to begin penetrating this market in calendar 2023 and beyond as we leverage our high-quality BAW technology and our new packaging technologies."

07:46 EDT AstroNova acquires Astro Machine for $17.1M in cash - AstroNova announced the acquisition of Astro Machine, for an aggregate purchase price of $17.1M in cash, from its founding family. Astro Machine is a designer and manufacturer of professional color and monochrome inkjet printers as well as a wide range of media handling equipment for labeling and mailing applications. The acquisition includes Astro Machine's 34,000-square-foot engineering and manufacturing plant in Elk Grove Village, Illinois. The transaction was funded with borrowings from an amended version of the company's existing senior bank debt facilities. The acquisition is expected to be accretive to earnings in the current fiscal year.

07:45 EDT Guru Organic Energy becomes energy drink partner for CEBL - GURU Organic Energy announced its first sports partnership, as the exclusive energy drink partner for the Canadian Elite Basketball League Championship weekend. The CEBL partnership includes a comprehensive media plan that comprises broadcast brand advertising and fun-filled activation opportunities within the weekend events. The CEBL Championship weekend is a five-day event taking place at various locations in Ottawa from August 10 to 14, featuring the run for the CEBL Championship trophy at TD Place Arena alongside a slate of exciting activities, including a street festival, a concert line-up of top performers, basketball events and playful activities designed to engage the community. The CEBL's vision aligns with GURU's own values when it comes to strengthening relations with local communities and supporting them through various initiatives. The CEBL is more than just basketball; it's about community, art, music, lifestyle and much more.

07:44 EDT Martin Marietta to sell California cement plant for $350M in cash - Martin Marietta Materials announced that it has entered into a definitive agreement to sell the Tehachapi, California cement plant and related distribution terminals to CalPortland Company for $350 million in cash. The transaction is expected to close in the first half of 2023, subject to regulatory approvals and other customary closing conditions.

07:42 EDT Xilio Therapeutics appoints Uli Bialucha as CSO - Xilio announced the promotions of Uli Bialucha, Ph.D., to chief scientific officer and Chris Frankenfield to chief legal and administrative officer, each effective as of August 8, 2022. Dr. Bialucha previously served as the company's senior vice president of research since April 2021,and Mr. Frankenfield previously served as the company's general counsel since March 2021.

07:40 EDT Xilio Therapeutics announces preliminary Phase 1 dose-escalation data for XTX101 - XTX101, an Fc-enhanced, tumor-selective anti-CTLA-4, is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors. The target dose level for XTX101 of 60 mg is anticipated to provide anti-tumor activity similar to ipilimumab at 10 mg/kg based on the 10 times greater potency observed for XTX101 relative to an ipilimumab analogue in preclinical studies. As of August 5, 2022, 12 patients have been treated with XTX101 in the monotherapy dose-escalation cohort at four dose levels ranging from 7 mg to 180 mg: The 180 mg dose level has surpassed the 60 mg target dose level for XTX101. As a result, Xilio recently expanded enrollment at the 180 mg dose level. A maximum tolerated dose has not yet been determined, and enrollment in the dose-escalation cohort is ongoing. Preliminary pharmacokinetic analyses demonstrated dose-proportional drug exposure, with limited active XTX101 in peripheral circulation consistent with PK data observed in preclinical studies. Additional XTX101 Development Updates: Xilio recently opened Part 1B of the clinical trial for patient enrollment, which is a monotherapy cohort designed to evaluate anti-tumor activity, including intra-tumoral PK and pharmacodynamic data, in patients with anti-CTLA-4 sensitive tumor types, with the goal of characterizing the anti-tumor activity of XTX101 at one or more dose levels selected in Part 1A of the trial. Given the potential for Fc-enhanced anti-CTLA-4 agents like XTX101 to demonstrate activity in tumors that are historically resistant to immuno-oncology treatment, Xilio plans to explore evaluating XTX101 in a Phase 2 clinical trial in patients with microsatellite stable colorectal cancer in combination with an anti-PD(L)-1.

07:38 EDT Norwegian Cruise Line 'encouraged' by continued strong consumer demand

07:34 EDT Sensei Biotherapeutics expects cash to fund operations into 1Q25 - Cash, cash equivalents and marketable securities were $123.7 million as of June 30, 2022, as compared to $147.6 million as of December 31, 2021. Sensei expects its current cash balance to fund operations into the first quarter of 2025.

07:32 EDT Sophia Genetics sees cash runway through 2025 and beyond

07:26 EDT Reata Pharmaceuticals: FDA extends review timeline for NDA for omaveloxolone - "Reata Pharmaceuticals announced that on August 8, after the U.S. financial markets closed, we received a communication from the U.S. FDA informing us that they have extended the review timeline for the New Drug Application for omaveloxolone for the treatment of Friedreich's ataxia by three months."

07:20 EDT Kymera Therapeutics expects cash to fund operations into 2025 - As of June 30, 2022, Kymera had approximately $482.5 million in cash, cash equivalents, and investments. Kymera expects that its cash, cash equivalents, excluding any future potential milestones from collaborations, will enable the Company to fund its operational plans into 2025 while the Company continues to identify opportunities to accelerate growth and expand its pipeline, technologies, and clinical indications.

07:18 EDT TransDigm says 2022 guidance 'remains suspended' - Cites continued disruption in primary commercial end markets.

07:17 EDT TransDigm declares special cash dividend of $18.50 per share - The company announced that its Board of Directors has authorized and declared a special cash dividend of $18.50 on each outstanding share of common stock and cash dividend equivalent payments under options granted under its stock options plans. The record date for the special dividend is August 19 and the payment date for the dividend is August 26.

07:14 EDT MarineMax to acquire Island Global Yachting for $480M in cash - MarineMax announced that it has entered into a definitive agreement to acquire Island Global Yachting, which owns and operates a collection of iconic marina assets and a yacht management platform in key global yachting destinations. MarineMax will acquire IGY Marinas for $480M in cash, with an additional potential earnout of up to $100M two years after closing, subject to the achievement of defined performance metrics. IGY Marinas, through recent acquisitions and organic growth, is projected to generate over $100 million of revenue in calendar 2022. Subject to the satisfaction of customary closing conditions, MarineMax expects the acquisition to close in the first half of fiscal 2023 and to be accretive within the first twelve months of closing. IGY Marinas will maintain its luxury branding that is well recognized as best-in-class in the global marina and superyacht communities. Tom Mukamal, CEO of IGY Marinas, and the IGY Marinas existing management team will continue to lead the growth and operations of the business.

07:13 EDT Cogent Biosciences expects cash to fund operations into 2025 - As of June 30, 2022, cash and cash equivalents were $325.6 million, as compared to $191.0 million as of March 31, 2022. The company believes that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into 2025.

07:11 EDT Achilles Therapeutics expects cash to fund operations into 2Q25 - Cash and cash equivalents were $201.6 million as of June 30, 2022, as compared to $266.3 million as of December 31, 2021. The Company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second quarter of 2025, including completion of the ongoing Phase I/IIa CHIRON and THETIS clinical trials.

07:11 EDT FedEx to pilot ten Ford E-Transit vans across SameDay City network - FedEx Office, a subsidiary of FedEx (FDX), in collaboration with Ford Pro (F), announced it is piloting ten Ford E-Transit vans across its FedEx SameDay City network as part of the goal to transition its entire pickup and delivery fleet to zero tailpipe emission vehicles by 2040 in alignment with the overall fleet electrification goal for FedEx. FedEx SameDay City is the company's local shipping option, which offers door-to-door delivery of time-sensitive parcels within hours with real-time notifications. The vehicles are being tested in nine markets coast-to-coast to assess performance in different road and weather conditions: Chandler, Arizona, Newark, California, Boca Raton, Florida, Clearwater, Florida, Plantation, Florida, Chicago, Illinois, Madison Heights, Michigan, Allen, Texas and Frisco, Texas. FedEx Office has installed charging stations dedicated to these vehicles at each van's home location and will supplement with remote charging stations in each market as needed to meet charging needs along courier routes.

07:09 EDT Galera expects cash to fund operations for at least next twelve months - As of June 30, 2022, Galera had cash, cash equivalents and short-term investments of $52.0 million. Galera expects that its existing cash, cash equivalents and short-term investments will enable Galera to fund its operating expenses and capital expenditure requirements for at least the next twelve months.

07:07 EDT Freeline expects cash to fund operating expenses into 2H23 - Unrestricted cash and cash equivalents were $90.0 million as of June 30, 2022, as compared to $117.7 million as of year-end 2021. Freeline expects that its current level of cash and cash equivalents will enable the company to fund its operating expenses into the second half of 2023.

07:04 EDT Denison Mines makes further proposal to acquire UEX Corp. for 51c per share - Denison Mines (DNN) has made a further proposal to acquire all of the issued and outstanding shares of UEX Corporation (UEXCF). Under the terms of the acquisition proposal, UEX shareholders would receive 0.32 shares of Denison in exchange for each share of UEX held, which represents an implied purchase price of 51c per UEX share, on a spot basis, as of the market close on August 8. Denison's acquisition proposal represents a 7% premium to the price implied by the amended arrangement agreement between UEX and Uranium Energy (UEC) dated August 5 based on the one-day volume weighted average price on August 8 and a 9% premium to the 20-day volume weighted average price implied by the amended UEC agreement. In order for the UEX board of directors to consider if the acquisition proposal constitutes a "superior proposal" under the Amended UEC agreement, UEX announced that it has postponed the special meeting of UEX securityholders, originally scheduled for August 9 to August 15. Denison's acquisition proposal is conditional on UEX terminating the amended UEC agreement, which will require the UEX board of directors to assess the acquisition proposal to be a "superior proposal" and that UEC has failed to match in accordance with the terms of the amended UEC agreement. UEX has been provided with a set of definitive documents to give effect to the acquisition proposal on a binding basis, and the parties would be in a position to complete the transaction without undue delay. After UEX determined that Denison's prior offer of July 22 constituted a "superior proposal", UEX and Denison negotiated and settled the terms of the necessary agreements. Additionally, the definitive documents have already been approved by the Denison board of directors.

06:58 EDT Becton Dickinson, Labcorp announce CDx collaboration agreement - Becton Dickinson (BDX) announced a collaboration agreement with Labcorp (LH), creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics, or CDx, intended to match patients with life-changing treatments for cancer and other diseases. The agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners. The two companies bring together capabilities that comprise an end-to-end solution for CDx development for the pharmaceutical industry. Their joint offering ranges from exploratory panel development to FDA approval of diagnostic and IVD kit manufacturing and distribution.

06:54 EDT Signet Jewelers to acquire Blue Nile for $360M in cash, sees accretion in FY24 - Signet Jewelers announced it has signed a definitive agreement to acquire Blue Nile, an online retailer of engagement rings and fine jewelry, for $360M in an all cash transaction. Blue Nile delivered revenue of more than $500M in calendar year 2021. The transaction will be funded with cash on hand and is currently expected to close in the third quarter of FY23. Regulatory filings were made in July and the applicable waiting period has passed however the transaction is still subject to other customary closing conditions. While synergies are likely to start materializing as early as the fourth quarter of FY23, the acquisition, will likely not be accretive until Q4 of FY24, exclusive of transaction and integration-related charges, as well as anticipated impacts of purchase accounting adjustments related to the transaction.

06:48 EDT Wireless Telecom sees Q3 bookings $8M-$10M - Tim Whelan, CEO of Wireless Telecom Group, stated, "We believe the pressures that impacted our Q2 results will ease in the second half of this year. We expect that our order flow will significantly improve in the third quarter which will lead to a reacceleration of year-over-year growth for the remainder of the year. Our current bookings and contract expectations for the Q3 are approximately $8M-$10M providing a basis for reaccelerating revenue growth in the 2022 second half. If the timing of supply chain delivery improves, we have additional revenue opportunities in the next two quarters, which further increases our basis for growth this year. Additionally, as announced at the annual shareholders meeting on July 29, 2022 we are undergoing a comprehensive strategic review process with CDX Advisors, a tech-enabled investment bank. We have various scenarios under evaluation including the sale of the entire Company or the sale of one or both segments separately. Our goal is to unlock and maximize shareholder value."

06:46 EDT Hormel Foods announces new operating model - Hormel Foods announced a new strategic operating model, aligning its businesses to be more agile, consumer and customer focused, and market driven. Effective October 31, the beginning of fiscal 2023, the company is transitioning to three operating segments - Retail, Foodservice and International. The One Supply Chain team will continue to oversee the company's global supply chain.

06:34 EDT Aramark reports 'record-level new client wins' - Aramark is driving positive business momentum through record-level new client wins, strong account retention rates, and enhanced pricing strategies, as well as from ongoing base revenue recovery. Net New Business in the first three quarters of fiscal 2022 already exceeds the record full year results in fiscal 2021. The company's margins have progressed since fiscal 2021 led by cost management and operating leverage from higher revenue levels, partially offset by the impact of inflation and new business start-up costs. Aramark is utilizing its extensive operating capabilities and resources-including purchasing scale, menu reengineering, labor optimization, and technology deployment, among others-to manage through this inflationary period, in close partnership with clients. Last quarter, Aramark announced a plan to separate its Uniforms segment into an independent, publicly traded company in a spin-off intended to be tax-free to Aramark and its stockholders. The company has made progress in the operational separation and added leaders with extensive public company experience to complement the deep industry experience already in place. This team is expected to lead the independent company upon completion of the spin-off. The company currently expects the spin-off to occur in the second half of fiscal 2023.

06:18 EDT Huntsman to sell Textile Effects division to Archroma for $718M - Huntsman announced it has entered into a definitive agreement to sell its Textile Effects division to Archroma, a portfolio company of SK Capital Partners. The total enterprise value of the transaction is approximately $718M, which includes the assumption of approximately $125M in net underfunded pension liabilities as of December 31, 2021. The acquisition is being partially funded with preferred equity, of which Huntsman is taking up to $80M, an amount SK Capital Partners will seek to syndicate prior to the transaction closing. Over the last twelve months ending June 30, the Textile Effects division reported sales of $772M and adjusted EBITDA of $94M. Huntsman anticipates cash taxes on the transaction of approximately $50M. Huntsman intends to report Textile Effects as discontinued operations beginning in the third quarter of 2022. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close in the first half of 2023.

06:15 EDT Google back up after brief outage Monday night, says Downdetector - Google services appear to be back up after facing a brief global disruption on late Monday, according to Downdetector. At the peak of outage, more than 30,000 user reports had indicated issues with Google in the U.S. Reference Link

06:10 EDT Groupon sees 15%-20% sustainable annual adjusted EBITDA margins in 2023 - In slides being presented on its Q2 earnings conference call, Groupon said it believes its turnaround strategy will allow it to fundamentally reposition its business to grow profitably in a variety of economic cycles and position the company for long-term growth and value creation. Groupon plans to "aggressively" right size its tech organization and reduce the size of its North America sales force. The company looks to create a business model with goal of generating positive free cash flow every quarter, starting in Q4. It sees 15%-20% sustainable annual adjusted EBITDA margins in 2023 and beyond, as well as $100M in annual free cash fllow.

06:05 EDT Spirit Airlines sees Q3 fuel cost per gallon $3.55-$3.60 - Sees Q3 adjusted operating expenses $1.32B-$1.33B. Sees Q3 effective tax rate 21%.

06:02 EDT BeiGene says Phase 3 RATIONALE 301 trial met primary endpoint - BeiGene announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival versus sorafenib as a first-line treatment in adult patients with unresectable hepatocellular carcinoma. The safety profile for tislelizumab was consistent with previous studies and no new safety signals were reported. More than 600 patients in the U.S., Europe, and Asia participated in the study.

05:19 EDT Akanda, Cansativa announce medical cannabis cooperation in Germany - Akanda and Cansativa jointly announced a new cooperation that will soon allow German pharmacies to provide patients with two novel cannabis cultivars. This collaboration allows the Cansativa platform to supply the German market with dried flowers from Akanda's EU-GMP certified indoor grow facility in Sintra, Portugal. Akanda is expected to deliver at least 1,000 kilograms to Cansativa over the first 12-month term of the agreement. All pharmacies in Germany will be able to purchase these products through the Cansativa platform.

05:14 EDT ASE Technology reports July revenue $1.95B vs. $1.67B last year, up 17% - Reports July ATM revenue $1.12B vs. 1.05B last year, up 7%.

05:07 EDT Hutchmed, Inmagene Biopharmaceuticals dose first patient in IMG-004 study - Inmagene Biopharmaceuticals and Hutchmed announced that the first participant, based in the United States, was dosed in a global Phase I trial of IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase, or BTK, inhibitor. Inmagene is developing the drug candidate to potentially treat immunological diseases.